Vaxil Bio

Vaxil Bio Ltd. is an immunotherapy biotechnology company based in Toronto, Canada, that specializes in drug discovery and development using a unique platform centered on signal peptides. The company's lead product, ImMucin, has successfully completed a Phase I/II clinical trial aimed at treating multiple myeloma. In addition to cancer therapies, Vaxil Bio is working on developing a tuberculosis vaccine and a coronavirus vaccine. The company has established collaborations with the Tel Aviv Sourasky Medical Center to advance a peptide vaccine against COVID-19 and with the U.S. Army Medical Research Institute of Infectious Diseases to evaluate its CorVax vaccine's efficacy in preventing COVID-19 in animal models. Founded in 2006, Vaxil Bio is at the forefront of creating innovative synthetic therapeutic and preventive vaccines, leveraging its proprietary VaxHit technology to enhance T and B-cell activation.